OXB has won the option to license a cystic fibrosis gene therapy in a collaboration with the Edinburgh 's OXB and Oxford BioMedica ( OXB ) to develop an inhaled, lentiviral vector-based treatment. Imperial Innovations, the technology transfer office for Imperial College London, played a leading role in setting up the project, which Boehringer thinks has the mix of capabilities needed to succeed. OXB will provide funding, along with research and development, to move the therapy through preclinical studies, while Cystic Fibrosis Gene Therapy Consortium will provide expertise in lentiviral-based vector production. Boehringer 's option to obtain the global rights to the therapy can be exercised during the research and development process.
OXB has won the option to license a cystic fibrosis gene therapy in a collaboration with the Edinburgh 's OXB and Oxford BioMedica ( OXB ) to develop an inhaled, lentiviral vector-based treatment. OXB will provide funding, along with research and development, to move the therapy through preclinical studies, while Cystic Fibrosis Gene Therapy Consortium will provide expertise in lentiviral-based vector production. Boehringer 's option to obtain the global rights to the therapy can be exercised during the research and development process.